HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Potential link between radiation exposure, cancer risk still debated
-
- Brentuximab vedotin improved response rates in relapsed, refractory Hodgkin’s lymphoma
- Early assessment of molecular response identified increased risk for treatment failure in CML
- FDA advisory panel unanimously recommends further evaluation of vandetanib
- Hestia criteria predicted patients with pulmonary embolism eligible for outpatient treatment
- Nilotinib associated with stable outcomes in Ph+CML
- ODAC rejects dutasteride, finasteride for prostate cancer prevention
- Scoring system stratified patients by recurrence risk of cancer-associated VTE
- A review of some of the year’s breakthroughs in hematology Harry S. Jacob, MD, DHC
-
- How optimism creates conflicts of interest Michael N. Needle, MD
- Targeted therapies usher in new era in cancer treatment Joseph R. Bertino, MD
- Blacks, Native Americans more likely to have high-risk neuroblastoma, poorer survival
- Two weeks in the life of a transplant doctor William Wood, MD
- Adjuvant TAC may improve survival in women with node-negative breast cancer
- Discontinuing bevacizumab did not lead to poorer outcomes
- Higher doses of radiation, methotrexate increased risk for second primary tumors of CNS
- Intravenous iron failed to improve erythropoietic response in patients with chemotherapy-induced anemia
-
- Intrathecal rituximab offers new approach to treatment of leptomeningeal malignancy Tiffany Capouch, PharmD